

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

Feasibility and safety of PIPAC combined with additional surgical procedures: PLUS study

This is a pre print version of the following article:

Original Citation:

Availability:

This version is available <http://hdl.handle.net/2318/1859192> since 2022-05-12T16:08:58Z

Published version:

DOI:10.1016/j.ejso.2022.05.001

Terms of use:

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

Feasibility and Safety of PIPAC combined with additional surgical procedures: PLUS Study.

Manuela Robella¹, Martin Hubner², Marc Reymond³, Vladimir Khomiakov⁴, Andrea di Giorgio⁵, Aditi Bhatt⁶, Naoual Bakrin⁷, Olivia Sgarbura^{8,9}, Wouter Willaert¹⁰, Mohammad Alyami^{7,11}, Hugo Teixeira², Andrey Kaprin⁴, Federica Ferracci⁵, Guillaume DeMeeus⁸, Paola Berchialla¹², Marco Vaira¹ and ISSPP PIPAC study group.

¹Unit of Surgical Oncology, Candiolo Cancer Institute, FPO – IRCCS

²Department of Visceral Surgery, Lausanne University Hospital CHUV, University of Lausanne (UNIL), Switzerland.

³Department of General & Transplant Surgery, University Hospital Tübingen, D-72076 Tübingen, Germany.

⁴Department of thoracoabdominal cancer surgery, P.A. Hertsen Moscow Research Oncological Institute – branch of the National Medical Research Center of Radiology, Moscow, Russia

⁵Surgical Unit of Peritoneum and Retroperitoneum, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.

⁶Department of Surgical Oncology, Zydus Hospital, Ahmedabad, India.

⁷Department of General Surgery and Surgical Oncology, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Pierre-Bénite, France.

⁸Department of Surgical Oncology, Cancer Institute Montpellier (ICM), University of Montpellier, Montpellier, France

⁹IRCM, Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Université de Montpellier, Institut régional du Cancer de Montpellier, Montpellier, F-34298, France.

¹⁰Department of GI Surgery, Ghent University Hospital, Ghent, Belgium.

¹¹Department of General Surgery and Surgical Oncology, Oncology Center, King Khalid Hospital, Najran, Saudi Arabia.

¹²Department of Clinical and Biological Sciences, University of Turin, Turin, 10124 Italy

Corresponding Author

Manuela Robella, MD

Unit of Surgical Oncology, Candiolo Cancer Institute, FPO – IRCCS

Str. Provinciale 142, Km 3.95

10060 Candiolo – Torino

Phone: +39 0119933630

manuela.robella@gmail.com

Abbreviations

PIPAC Pressurized IntraPeritoneal Aerosol Chemotherapy

PCI Peritoneal Cancer Index

IPTW Inverse Probability of Treatment Weighting

NCI National Cancer Institute

CTCAE Common Terminology Criteria for Adverse Events

CD Cisplatin+Doxorubicin

OX oxaliplatin

PLD pegylated liposomal doxorubicin

MMC mitomycin C

IQR interquartile range

OR odds ratio

CI Confidence Interval

PM Peritoneal Metastases

HIPEC Hyperthermic IntraPERitoneal Chemotherapy

Abstract

PIPAC (Pressurized IntraPeritoneal Aerosol Chemotherapy) is a minimally invasive approach relying on physical principles for improving intraperitoneal drug delivery, including optimizing the homogeneity of drug distribution through an aerosol, applying increased intraperitoneal hydrostatic pressure and limiting blood outflow during drug nebulization. Feasibility and safety of the new approach are now consolidated and data on its effectiveness are continuously increasing.

Although any surgical procedure associated with PIPAC had always been discouraged due to the high risk of complications, surgical practice is constantly changing: with growing expertise, more and more surgical teams associate PIPAC with surgery.

PLUS study is part of the retrospective international cohort studies including 10 centers around the world (India, Italy, France, Germany, Belgium, Russia, Saudi Arabia, Switzerland) and 96 cases of combined approaches: the procedures most frequently associated with PIPAC were not only adhesiolysis (n = 41), omentectomy (n = 17), adnexectomy (n = 29), umbilical / inguinal hernia repairs (n = 14) but also more demanding procedures such as intestinal resections (n = 2), gastrectomy (n = 7), splenectomy (n = 1), bowel repair/stoma creation (n = 6). Although the evidence is currently limited, PLUS study demonstrated, through a propensity score analysis, that PIPAC associated to additional surgical procedure is linked to an increase of surgical time ($p < 0.001$), length of stay ($p < 0.001$) and medical complication rate (odds ratio 15362; $p < 0.001$); the most frequently reported medical complications were mild or moderate in severity, such as abdominal pain, nausea, ileus and hyperthermia. No difference in terms of surgical complications was registered; neither reoperation or postoperative deaths were reported.

These results suggest that PIPAC can be safely combined in expert centers with additional surgeries. Widespread change of practice should be discouraged before the results of ongoing prospective studies are available.

Keywords

Surgery – peritoneal metastases / peritoneal cancer – PIPAC – complications

1. Introduction

In the last decade, Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) has emerged as new palliative treatment option for patients with peritoneal metastases. It is based on the use of aerosolized chemotherapy at an elevated intra-abdominal pressure by taking advantage of the physical properties of gas and pressure¹. Feasibility and safety of the new approach are now consolidated; the data on its effectiveness are continuously increasing: improvement in quality of life, diminishment of pain, ascites, abdominal distension and gastrointestinal symptoms. Despite its originally palliative intent, some patients had very good results in terms of histopathological/radiological response which allow the option for secondary curative surgery²⁻⁵.

Currently any surgical procedure (including adhesiolysis or bowel sutures) is considered contraindicated in combination with PIPAC due to the high rate of complications in the initial experience of PIPAC treatment^{6,7}.

Surgical practice is constantly changing and more and more surgical teams with the growth of expertise started to associate surgical procedures with PIPAC (although data have not yet been published); in this setting, two trial are investigating the combination of radical surgery for locally advanced gastric cancer in terms of postoperative adverse events and complications in one study (PIPAC-OPC 2 - ClinicalTrials.gov Identifier: NCT03287375) and overall and disease free survival in the other (GASPACCO - ClinicalTrials.gov Identifier: NCT04595929).

The aim of this multicenter retrospective cohort study (PLUS study) was to analyze feasibility and safety of PIPAC in combination with additional surgical procedures.

2. Material and methods

2.1 Participating centers and patient population

This retrospective analysis is part of the multi-center PIPAC cohort studies aimed at evaluating oncological efficacy of PIPAC treatment by disease entity. Study centers were certified to perform PIPAC and had a minimal experience of 60 procedures. All 19 study centers were invited to contribute patients also to this analysis.

The analysis included patients with histologically/cytologically confirmed advanced solid tumors with documented peritoneal carcinomatosis treated with PIPAC associated with any surgical procedure; as control group data about one PIPAC procedure not associated with surgery performed in the same patients were collected. In case of patients submitted to only one PIPAC and surgical procedure, a “matched” patient according to pathology and PCI (Peritoneal Cancer Index) has been included in the analysis.

2.2 Research methodology

Retrospective cases of surgery associated with PIPAC performed in all the centers authorized to carry out the procedure were collected with minimal case load according to the inclusion criteria of PIPAC cohort study. Collected information included demographic data, cancer-specific data, descriptive variables relating to the intervention (duration, surgical procedures performed, intraperitoneal drugs used, drugs doses etc..) and the postoperative period (length of stay, postoperative complications, reoperation rate, etc..).

This retrospective study received institutional review board approval by all participating centers. Considering the observational nature of the study and the use of pseudo-anonymized data, no informed consent from the patients was required.

2.3 Study end-points and statistical analysis

Primary objective of the study was postoperative morbidity rate within 30 days; secondary objectives were 30-days postoperative mortality, length of stay and reoperation rate.

To adjust for potential patient selection bias, attributable to non-randomized assignment, a propensity score analysis based on the inverse probability of treatment weighting (IPTW) was carried out to account for time-varying confounders.

The propensity score was estimated using logistic regression model, with the treatment strategies as the dependent variable and the following variables as covariates: age, tumor location, PCI, lines of chemotherapy and ascites.

A logistic regression weighted analysis was carried out on postoperative morbidity rate within 30 days, 30-days postoperative mortality and reoperation rate, whereas a weighted linear regression analysis was carried out on length of stay.

2.4 Treatment

Technique, safety protocol, and treatment regimens were standardized among expert centers⁵⁻⁷. The abdomen was accessed with a single port access or one 10/12-mm (nebulizer) and one 5-mm (optical) trocar⁸. The abdomen was insufflated with CO₂ (12 mmHg). Ascites was removed and the amount quantified; in case there was no ascites, a peritoneal washing was performed for cytology examination. The abdominal cavity was explored and the disease evaluated with PCI.

The chemotherapy injections were remote-controlled; the flow rate was 30 ml/min and the maximal upstream pressure was 290 psi. The aerosol was maintained for 30 min at 37°C and then exsufflated via a closed line over two sequential micro-particle filters into the air waste system of the hospital.

Perioperative morbidity was classified according to Clavien-Dindo classification for surgical complications and the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 for medical complications.

3. Results

3.1 Patient's characteristics and treatment

This multicentric, retrospective study was conducted in Italian (Turin n = 50; Rome n = 16), Swiss (n = 34), Belgian (n = 8), French (Lyon n = 16; Montpellier n = 10), Russian (n = 21), German (n = 34), Indian (n = 16) and Saudi (n = 4) hospitals. Patients were treated between January 2018 and December 2020.

Of the 209 patients selected from the dataset, 196 were included in the analysis (13 cases were excluded due to missing data): 96 underwent PIPAC + additional surgical procedures (PIPAC+SP) and 100 PIPAC alone. Table 1 lists patients' demographic and clinical features before and after IPTW adjustment. Before propensity adjustment, compared with patients submitted to PIPAC alone, the PIPAC+SP group consisted of more females (68.8% vs 58%, p = 0.158) and had more frequently received concomitant systemic chemotherapy (58.2% vs 51.7%, p = 0.470): on the whole, the two groups are in any case homogeneous.

Symptoms reported by the patients before the procedure were evaluated: the details are listed in Table 2.

The most frequent surgical procedures performed were adhesiolysis, oophorectomy, omentectomy; the detailed description is reported in Figure 1. The most frequent PIPAC drug regimens included cisplatin and doxorubicin (CD), 7.5 to 30 mg/m² and 1.5 to 6 mg/m², respectively; oxaliplatin (OX) 92 to 135 mg/m². In rare cases abraxane, pegylated liposomal doxorubicin (PLD) and mitomycin C (MMC) were used. Specifics about drug type and dose are listed in Table 3.

3.2 Outcome analysis

Compared with the PIPAC-alone group, the PIPAC+SP group had longer median surgical times (120 minutes [90-159 IQR] vs 90 minutes [75-105 IQR]; p < 0.001) and longer median hospital stay (3 days [3-5 IQR] vs 3 days [2-3 IQR]; p < 0.001). A mean increase of 52.23 minutes and 1.82 days was reported, respectively (CI 36.22 – 68.23; CI 1.05 – 2.59).

Neither reoperations nor deaths were registered in either group.

Surgical complication rate was similar between PIPAC+SP and PIPAC alone (5.2% vs 2%, respectively; OR = 2.52, 95% CI, 0.47 – 13.55). The surgical complications were essentially wound infections (n = 3) and bleeding (n = 2), in all cases Clavien – Dindo grade 2.

Within the whole cohort, medical complication rate was significantly different between the two groups: 3% in PIPAC group and 30.2% in PIPAC+SP group (odds ratio 15.62, 95% CI 4.54 – 53.73; p < 0.001). Analyzing in detail the medical complications, the most frequently reported were abdominal pain (24%), nausea (3.1%), ileus (6.2%) and hyperthermia (2.1%).

The relationship between the number of PIPAC associated with surgery (the first or any subsequent PIPACs) and the other outcomes was investigated: 43 patients were submitted to surgery during the first PIPAC procedure, 34 during a subsequent PIPAC. No difference in terms of surgical complications (7.0% vs 5.9%, odds ratio 0.83, 95% CI 0.10 – 5.32; p = 0.847), medical complications (16.3% vs 8.8%, odds ratio 0.50, 95% CI 0.10 – 1.96; p = 0.341), hospital stay (4 days vs 3 days, mean difference -0.60, 95% CI -2.11 – 0.90; p = 0.433) and surgical time (120 min vs 132 min, mean difference 17.14, 95% CI -11.46 – 46.75; p = 0.244) were reported.

4. Discussion

Born essentially with the palliative aim of alleviating symptoms, in particular to control ascites leading to a better quality of life, the histological evidence of tumor regression in patients with PM (Peritoneal Metastases) of gastric, appendiceal, and ovarian origin submitted to PIPAC dates back in 2014¹. Feasibility and safety of PIPAC are now consolidated and data on its effectiveness are continuously increasing. Multiple studies showed that about 75% of patients with unresectable PM develop major or complete intraperitoneal tumor regression assessed by histology, after repeated PIPAC treatment⁹⁻¹⁴.

In this international cohort, the addition of surgical procedures to PIPAC led to longer surgery time, higher rate of minor medical complications and longer hospital stay, while no difference in major surgical complications was detected. Most of the associated surgical procedures were of limited complexity: hernia repairs, omentectomy, adnexectomy; however, we must notice that even more complex procedures (intestinal resections, full-thickness intestinal repairs and gastrectomies) combined with PIPAC did not lead to any surgical complications. Furthermore, the medical complications recorded were all mild or moderate. Anyway, safety of combined gastrointestinal resection + PIPAC needs to be confirmed through ongoing prospective studies before this practice can be recommended.

To support this recommendation, an animal study used a healthy swine model to compare the postoperative anastomotic leakage rate between PIPAC and HIPEC with digestive resection and to analyze macro- and microcirculation parameters: PIPAC might have increased anastomotic leakage incidence compared to HIPEC (37.5% vs 0%). Conclusion of the authors was the warning to use PIPAC with digestive resection and the recommendation to avoid PIPAC in cases of perioperative serosal injury¹⁵.

If good results in terms of survival have been obtained with PIPAC alone, possibly associated with systemic chemotherapy, in a palliative setting, the chance of combining PIPAC with surgical procedures (in case of safety profile confirmation) can open up new perspectives for use for this innovative approach. In this regard, the Odense group recently published promising results in PM from gastric cancer: objective tumor response was documented in 40% of the patients after PIPAC, including complete histological regression in some, whereas an additional 20% had no further tumor progression¹⁶. Based on these observations, they started a study (PIPAC-OPC 2 - NCT03287375) about PIPAC delivered immediately after a laparoscopic gastrectomy for gastric cancer, in order to evaluate, as primary outcomes, medical adverse events and surgical complications. Similarly, a Russian group is conducting a prospective randomized study in which patients undergoing radical surgery for locally advanced gastric cancer and a high risk of developing peritoneal carcinomatosis can receive as adjuvant treatment systemic chemotherapy with or without PIPAC (GASPACCO - NCT04595929): aim of the study is overall and progression free survival evaluation in the two groups. Considering the known complications of cytoreductive surgery associated with HIPEC, the possibility in the future of replacing it with PIPAC, with lower dosages and equal efficacy, would open new scenarios for this method. Large series studying cytoreductive surgery + HIPEC have shown a complication rate (Clavien-Dindo classification grade III – IV) between 22 and 34% and a 30-day mortality rate between 1 and 4%¹⁷⁻¹⁹. Extent of the peritoneal metastases and hereby extent of the surgical procedures are main factors in predicting the risk of complications²⁰. For this reason, given the type of procedures performed within this study and their extent, the results need confirmation by trials in which PIPAC is combined with major surgery.

The good results in terms of surgical postoperative morbidity could be explained by the high quality and experience of the participating centers that are a strength of this study. Therefore, despite the promising and reassuring results obtained, it is recommended not to use the PIPAC possibly associated with surgical procedures, in the absence of adequate experience not only in peritoneal carcinomatosis treatment, but also in PIPAC administration.

Overall the quality of the study data is good: patients were not included if data about the extent of peritoneal carcinomatosis, surgery, PIPAC and postoperative morbidity were missing. The propensity score based on IPTW adjustment significantly reduces confounding bias potentially offering estimation of treatment effect similar to randomized trials.

The limitations of the study are related to its retrospective nature and the presence of multiple variables regarding drug type and drug dose. This aspect is in line with what has been published in a recent survey: PIPAC procedure is being performed with a uniform concern for safety but with an increasing variability related to surgical aspects, chemotherapy regimens and response evaluation²¹. In this scenario, numerous phase 1 studies have been published to date about PIPAC-CD^{22,23} and PIPAC-OX^{22,24,25} and are ongoing for Abraxane²⁶. A retrospective study reported data on the use of PLD²⁷, while there is little information on the use of mitomycin C²⁸. A potential explanation of this heterogeneity would be the lack of any other treatment options for this patient's setting in combination with the need to make the most of a treatment that is generally well tolerated. This flourishing of studies testifies to the rapid evolution of the method, but further diversification of protocols in the absence of new evidence should be prevented: to this end, recent consensus guidelines has been published to facilitate benchmarking and analysis of outcomes²⁹.

5. Conclusions

This cohort study found that the association of surgical procedures and PIPAC was safe and feasible. This combination may represent a valuable treatment option for selected patients submitted to radical surgery with a high risk of developing peritoneal carcinomatosis. Confirmation by the ongoing clinical trials is warranted and could open new perspective for PIPAC application.

References

1. Solass W, Kerb R, Mürdter T, et al. Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy. *Ann Surg Oncol* 2014;21(2):553-9. (In eng). DOI: 10.1245/s10434-013-3213-1.
2. Solass W, Giger-Pabst U, Zieren J, Reymond MA. Pressurized intraperitoneal aerosol chemotherapy (PIPAC): occupational health and safety aspects. *Ann Surg Oncol* 2013;20(11):3504-11. (In eng). DOI: 10.1245/s10434-013-3039-x.
3. Grass F, Vuagniaux A, Teixeira-Farinha H, Lehmann K, Demartines N, Hübner M. Systematic review of pressurized intraperitoneal aerosol chemotherapy for the treatment of advanced peritoneal carcinomatosis. *Br J Surg* 2017;104(6):669-678. (In eng). DOI: 10.1002/bjs.10521.
4. Tempfer C, Giger-Pabst U, Hilal Z, Dogan A, Rezniczek GA. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal carcinomatosis: systematic review of clinical and experimental evidence with special emphasis on ovarian cancer. *Arch Gynecol Obstet* 2018;298(2):243-257. (In eng). DOI: 10.1007/s00404-018-4784-7.
5. Alyami M, Hübner M, Grass F, et al. Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications. *Lancet Oncol* 2019;20(7):e368-e377. (In eng). DOI: 10.1016/S1470-2045(19)30318-3.
6. Hübner M, Grass F, Teixeira-Farinha H, Pache B, Mathevet P, Demartines N. Pressurized IntraPeritoneal Aerosol Chemotherapy - Practical aspects. *Eur J Surg Oncol* 2017;43(6):1102-1109. (In eng). DOI: 10.1016/j.ejso.2017.03.019.
7. Giger-Pabst U, Tempfer CB. How to Perform Safe and Technically Optimized Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC): Experience After a Consecutive Series of 1200 Procedures. *J Gastrointest Surg* 2018;22(12):2187-2193. (In eng). DOI: 10.1007/s11605-018-3916-5.
8. Vaira M, Robella M, Borsano A, De Simone M. Single-port access for Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC): technique, feasibility and safety. *Pleura Peritoneum* 2016;1(4):217-222. (In eng). DOI: 10.1515/pp-2016-0021.
9. Robella M, Vaira M, De Simone M. Safety and feasibility of pressurized intraperitoneal aerosol chemotherapy (PIPAC) associated with systemic chemotherapy: an innovative approach to treat peritoneal carcinomatosis. *World J Surg Oncol* 2016;14:128. (In eng). DOI: 10.1186/s12957-016-0892-7.
10. Tempfer CB, Winnekendonk G, Solass W, et al. Pressurized intraperitoneal aerosol chemotherapy in women with recurrent ovarian cancer: A phase 2 study. *Gynecol Oncol* 2015;137(2):223-8. (In eng). DOI: 10.1016/j.ygyno.2015.02.009.
11. Demtröder C, Solass W, Zieren J, Strumberg D, Giger-Pabst U, Reymond MA. Pressurized intraperitoneal aerosol chemotherapy with oxaliplatin in colorectal peritoneal metastasis. *Colorectal Dis* 2016;18(4):364-71. (In eng). DOI: 10.1111/codi.13130.
12. Nadiradze G, Giger-Pabst U, Zieren J, Strumberg D, Solass W, Reymond MA. Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Low-Dose Cisplatin and Doxorubicin in Gastric Peritoneal Metastasis. *J Gastrointest Surg* 2016;20(2):367-73. (In eng). DOI: 10.1007/s11605-015-2995-9.
13. Struller F, Horvath P, Solass W, et al. Pressurized intraperitoneal aerosol chemotherapy with low-dose cisplatin and doxorubicin (PIPAC C/D) in patients with gastric cancer and peritoneal metastasis: a phase II study. *Ther Adv Med Oncol* 2019;11:1758835919846402. (In eng). DOI: 10.1177/1758835919846402.
14. De Simone M, Vaira M, Argenziano M, et al. Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Oxaliplatin, Cisplatin, and Doxorubicin in Patients with Peritoneal Carcinomatosis: An Open-Label, Single-Arm, Phase II Clinical Trial. *Biomedicines* 2020;8(5) (In eng). DOI: 10.3390/biomedicines8050102.
15. Tavernier C, Passot G, Vassal O, et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) might increase the risk of anastomotic leakage compared to HIPEC: an experimental study. *Surg Endosc* 2020;34(7):2939-2946. (In eng). DOI: 10.1007/s00464-019-07076-3.
16. Ellebæk SB, Graversen M, Detlefsen S, et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) of peritoneal metastasis from gastric cancer: a descriptive cohort study. *Clin Exp Metastasis* 2020;37(2):325-332. (In eng). DOI: 10.1007/s10585-020-10023-5.

17. Verwaal VJ, van Tinteren H, Ruth SV, Zoetmulder FA. Toxicity of cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy. *J Surg Oncol* 2004;85(2):61-7. (In eng). DOI: 10.1002/jso.20013.
18. Smeenk RM, Verwaal VJ, Zoetmulder FA. Toxicity and mortality of cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei--a report of 103 procedures. *Eur J Surg Oncol* 2006;32(2):186-90. (In eng). DOI: 10.1016/j.ejso.2005.08.009.
19. Simkens GA, Verwaal VJ, Lemmens VE, Rutten HJ, de Hingh IH. Short-term outcome in patients treated with cytoreduction and HIPEC compared to conventional colon cancer surgery. *Medicine (Baltimore)* 2016;95(41):e5111. (In eng). DOI: 10.1097/MD.0000000000005111.
20. Verwaal VJ, Funder JA, Sørensen MM, Iversen LH. The impact of postoperative complications following cytoreductive surgery combined with oxaliplatin based heated intraperitoneal chemotherapy. *Eur J Surg Oncol* 2021 (In eng). DOI: 10.1016/j.ejso.2021.08.027.
21. Sgarbura O, Villeneuve L, Alyami M, et al. Current practice of pressurized intraperitoneal aerosol chemotherapy (PIPAC): Still standardized or on the verge of diversification? *Eur J Surg Oncol* 2020 (In eng). DOI: 10.1016/j.ejso.2020.08.020.
22. Robella M, De Simone M, Berchiolla P, et al. A Phase I Dose Escalation Study of Oxaliplatin, Cisplatin and Doxorubicin Applied as PIPAC in Patients with Peritoneal Carcinomatosis. *Cancers (Basel)* 2021;13(5) (In eng). DOI: 10.3390/cancers13051060.
23. Tempfer CB, Giger-Pabst U, Seebacher V, Petersen M, Dogan A, Rezniczek GA. A phase I, single-arm, open-label, dose escalation study of intraperitoneal cisplatin and doxorubicin in patients with recurrent ovarian cancer and peritoneal carcinomatosis. *Gynecol Oncol* 2018;150(1):23-30. (In eng). DOI: 10.1016/j.ygyno.2018.05.001.
24. Kim G, Tan HL, Sundar R, et al. PIPAC-OX: A Phase I Study of Oxaliplatin-Based Pressurized Intraperitoneal Aerosol Chemotherapy in Patients with Peritoneal Metastases. *Clin Cancer Res* 2020 (In eng). DOI: 10.1158/1078-0432.CCR-20-2152.
25. Dumont F, Senellart H, Pein F, et al. Phase I/II study of oxaliplatin dose escalation via a laparoscopic approach using pressurized aerosol intraperitoneal chemotherapy (PIPOX trial) for nonresectable peritoneal metastases of digestive cancers (stomach, small bowel and colorectal): Rationale and design. *Pleura Peritoneum* 2018;3(3):20180120. (In eng). DOI: 10.1515/pp-2018-0120.
26. Van De Sande L, Graversen M, Hubner M, et al. Intraperitoneal aerosolization of albumin-stabilized paclitaxel nanoparticles (Abraxane™) for peritoneal carcinomatosis - a phase I first-in-human study. *Pleura Peritoneum* 2018;3(2):20180112. (In eng). DOI: 10.1515/pp-2018-0112.
27. Robella M, Vaira M, Argenziano M, et al. Exploring the Use of Pegylated Liposomal Doxorubicin (Caelyx). *Front Pharmacol* 2019;10:669. (In eng). DOI: 10.3389/fphar.2019.00669.
28. Alyami M, Gagniere J, Sgarbura O, et al. Multicentric initial experience with the use of the pressurized intraperitoneal aerosol chemotherapy (PIPAC) in the management of unresectable peritoneal carcinomatosis. *Eur J Surg Oncol* 2017;43(11):2178-2183. (In eng). DOI: 10.1016/j.ejso.2017.09.010.
29. Hübner M, Alyami M, Villeneuve L, et al. Consensus guidelines for pressurized intraperitoneal aerosol chemotherapy: Technical aspects and treatment protocols. *Eur J Surg Oncol* 2021 (In eng). DOI: 10.1016/j.ejso.2021.10.028.

Figure 1. Surgical procedures




Table 1. Demographic and clinical features of patients before and after IPTW							
Factors	Study group, unweighted			Study group, weighted			
	PIPAC 100	PIPAC + SP 96	p	PIPAC 99.4	PIPAC + SP 96.2	p	SMD
Sex, male (%)	42 (42.0)	30 (31.2)	0.158	41 (41.0)	31 (31.8)	0.186	0.194
Age, mean (SD)	57.7 (12.3)	56.2 (12.8)	0.391	57.08 (12.26)	57.1 (13.02)	0.989	0.002
BMI, mean (SD)	23.9 (3.9)	24.2 (3.7)	0.728	24.05 (3.97)	24.15 (3.76)	0.857	0.026
ASA Score (%)							
1	13 (13.0)	21 (22.3)	0.345	14 (14.0)	20 (20.8)	0.535	0.214
2	56 (56.0)	50 (53.2)		55 (55.0)	51 (53.1)		
3	29 (29.0)	21(22.3)		28 (28.0)	21 (21.8)		
4	2 (2.0)	2 (2.1)		2 (2.0)	2 (2.1)		
ECOG Score (%)							
0	46 (51.1)	52 (60.5)	0.454	48 (53.3)	49 (57.7)	0.848	0.088
1	33 (36.7)	25 (29.1)		31 (34.7)	27 (30.9)		
2	11 (12.2)	9 (10.5)		11 (11.8)	10 (11.4)		
Karnofsky Index, mean (%)	90.2 (10.6)	91.4 (11.1)	0.510	90.56 (10.63)	91.07 (11.12)	0.769	0.046
Primary Cancer (%)							
Adrenal gland	0 (0.0)	1 (1.0)	0.996	0 (0.0)	1 (0.7)	1.000	0.123
PMP	12 (12.0)	12 (12.5)		12 (12.5)	12 (12.5)		
Cholangiocarcinoma	2 (2.0)	3 (3.1)		2 (2.5)	2 (2.6)		
Colorectal cancer	16 (16.0)	15 (15.6)		16 (16.0)	15 (16.0)		
DMPM	11 (11.0)	11 (11.5)		11 (11.3)	11 (11.3)		
Endometrial cancer	1 (1.0)	1 (1.0)		1 (1.0)	1 (1.0)		
Gastric cancer	45 (45.0)	39 (40.6)		42 (42.4)	40 (41.8)		
Ovarian cancer	10 (10.0)	11 (11.5)		11 (11.0)	10 (10.8)		
Pancreatic cancer	2 (2.0)	2 (2.1)		2 (2.2)	2 (2.2)		
Primary peritoneal cancer	1 (1.0)	1 (1.0)		1 (1.0)	1 (1.0)		
PCI, median (IQR)	18.0 (7.7-28.2)	15.0 (7.0-25.0)	0.313	15.9 (7.0- 26.0)	15.7 (7.0-25.4)	0.985	0.010
IV chemotherapy, yes (%)	45 (51.7)	53 (58.2)	0.470	44 (51.3)	54 (59.0)	0.314	0.154
sCT cycles, median (IQR)	9 (6-12)	8 (5-11.2)	0.875	9 (4.97)	8 (5.12)	0.320	0.145
Symptoms, yes (%)	49 (49.0)	52 (54.2)	0.562	47 (47.2)	54 (56.3)	0.209	0.183

Table 2. Symptoms' details before the procedure			
	PIPAC 100	PIPAC + SP 96	p
Pain, yes (%)	25 (25.0)	29 (30.2)	0.512
Ascites, yes (%)	32 (32.0)	27 (28.1)	0.663
Dysphagia, yes (%)	3 (3.0)	7 (7.3)	0.298
Obstructive symptoms/ stool alterations, yes (%)	4 (4.0)	12 (12.5)	0.056
Nausea, yes (%)	5 (5.0)	5 (5.2)	1.000

Table 3. Drug type and dose			
	PIPAC 100	PIPAC + SP 96	p
Abraxane 140 mg/m ² (%)	1 (1.0)	0 (0.0)	0.007
CDDP 7.5 mg/m ² + DXR 1.5 mg/m ² (%)	57 (57.0)	41 (42.7)	
CDDP 10.5 mg/m ² + DXR 2.1 mg/m ² (%)	8 (8.0)	28 (29.2)	
CDDP 15 mg/m ² + DXR 3 mg/m ² (%)	6 (6.0)	1 (1.0)	
CDDP 30 mg/m ² + DXR 6 mg/m ² (%)	2 (2.0)	0 (0.0)	
CDDP 7.5 mg/m ² + PLD 1.5 mg/m ² (%)	3 (3.0)	0 (0.0)	
CDDP 7.5 mg/m ² (%)	2 (2.0)	1 (1.0)	
MMC 10 mg/m ² (%)	0 (0.0)	1 (1.0)	
OXA 92 mg/m ² (%)	21 (21.0)	20 (20.8)	
OXA 135 mg/m ² (%)	1 (1.0)	2 (2.1)	
OXA 92 mg/m ² + MMC 1.5 mg/m ² (%)	0 (0.0)	1 (1.0)	

CDDP = cisplatin; DXR = doxorubicin; PLD = pegylated liposomal doxorubicin; MMC = mitomycin C; OXA = oxaliplatin

